Jun 15, 2020
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
Jun 08, 2020
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 06, 2020
Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic
Dec 09, 2019
DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant
Nov 06, 2019
Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM(TM), a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
Sep 26, 2019
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
Aug 09, 2019
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
Jun 26, 2019
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 18, 2019
Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM(TM)) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
Jun 02, 2019
DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant
Jun 02, 2019
Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma
May 15, 2019
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
Mar 26, 2019
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma
Dec 04, 2018
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Nov 07, 2018
Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Aug 08, 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
Aug 07, 2018
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202
May 31, 2018
Grifols Launches a New Testing Service for Patients Treated with Daratumumab